Clinical trial launches to see whether vitamin D helps treat multiple sclerosis

April 19th, 2012
Doctors at several centers across the U.S. are recruiting people who have multiple sclerosis (MS) to determine the effectiveness of high-dose vitamin D supplements for reducing MS disease activity. The vitamins would be added to standard therapy with glatiramer acetate (Copaxone®, Teva Pharmaceutical Industries). The study, funded by the National Multiple Sclerosis Society, is being led by Ellen Mowry, MD, MCR, at Johns Hopkins University in Baltimore. Other cities with centers recruiting participants include Portland, St. Louis, and San Francisco, and additional centers are being established.

A number of genetic and environmental factors influence whether a person will get MS. These factors may also impact the severity of the disease. Mounting evidence has been pointing to a reduced level of vitamin D in the blood as a risk factor for developing MS. In lab mice, vitamin D can reduce the effects of EAE, an MS-like disease, and growing evidence suggests it is time to test whether vitamin D can provide benefits to people who have MS.

Investigators are seeking 172 clinical trial participants between the ages of 18 and 50, who have been diagnosed with the relapsing-remitting form of MS. More details on the enrollment criteria are available at: http://www.clinicaltrials.gov/ct2/show/NCT01490502.

Participants will begin standard Copaxone treatment daily and will be randomly assigned to take the current recommended daily allowance of vitamin D or a high dose. The primary goal of the study is to determine whether vitamin D can reduce the proportion of people who experience a relapse. Other outcomes being studied include relapse rates, quality of life, brain tissue volume, disability progression, and safety.

More information:
www.clinicaltrials.gov/ct2/show/NCT01490502

Provided by National Multiple Sclerosis Society

This Phys.org Science News Wire page contains a press release issued by an organization mentioned above and is provided to you “as is” with little or no review from Phys.Org staff.

More news stories

Tissue regeneration using anti-inflammatory nanomolecules

Anyone who has suffered an injury can probably remember the after-effects, including pain, swelling or redness. These are signs that the body is fighting back against the injury. When tissue in the body is damaged, biological ...

Dinosaur footprints set for public display in Utah

A dry wash full of 112-million-year-old dinosaur tracks that include an ankylosaurus, dromaeosaurus and a menacing ancestor of the Tyrannosaurus rex, is set to open to the public this fall in Utah.

Obama offers new accommodations on birth control

The Obama administration will offer a new accommodation to religious nonprofits that object to covering birth control for their employees. The measure allows those groups to notify the government, rather than their insurance ...

Dead floppy drive: Kenya recycles global e-waste

In an industrial area outside Kenya's capital city, workers in hard hats and white masks take shiny new power drills to computer parts. This assembly line is not assembling, though. It is dismantling some ...

Towards renal artery stenosis treatment

Renal artery stenting to open blockages in the kidney arteries may benefit patients who have historically been excluded from modern clinical trials, according to new recommendations for renal artery stenosis e-published in ...